On June 1, Shionogi announced that its oral antiviral drug XOCOVA® (ensitrelvir) has received U.S. FDA approval for post-exposure prophylaxis (PEP) of COVID-19 in adolescents aged 12 years and older and in adult patients. This approval came more than two…
Johnson & Johnson (J&J) Presents Full Data from Phase 2b JASMINE Study of Nipocalimab in Systemic Lupus Erythematosus (SLE) at EULAR 2026 I. Introduction: The SLE Treatment Landscape is Being Reshaped Systemic lupus erythematosus (SLE) is a chronic autoimmune disease…
On June 11 local time, Roche announced that the U.S. FDA has accepted the company’s supplemental Biologics License Application (sBLA) seeking approval for atezolizumab (Tecentriq®) and atezolizumab and hyaluronidase injection (Tecentriq Hybreza®) in combination with chemotherapy as adjuvant treatment for…
On June 12 local time, Sanofi announced that the U.S. FDA has granted accelerated approval for Tzield (teplizumab-mzwv) to delay the decline in endogenous insulin secretion in children aged 8 to 17 years recently diagnosed with Stage 3 type 1…
On June 12 local time, AstraZeneca announced that its AKT inhibitor Truqap (capivasertib) has been approved for a new indication in the United States, in combination with abiraterone and prednisone, for the treatment of adult patients with PTEN-deficient metastatic hormone-naïve…
On June 11, the Clinicaltrials.gov official website showed that Biokin Pharmaceutical has registered a Phase III clinical trial, PANKU-Lung08, to evaluate the efficacy and safety of BL-B01D1 in combination with osimertinib versus osimertinib (a third-generation EGFR-TKI) monotherapy in patients with EGFR-mutant non-small…
According to the official website of the Shanghai Stock Exchange STAR Market, Trinomab’s IPO registration has become effective, and the company is about to be officially listed on the STAR Market. Trinomab adopted the fifth set of listing standards. Founded…
In May 2026, SYH2095 Tablets, co-developed by CSPC Pharmaceutical Group and Yingchuang Pharmaceutical, received approval from the CDE to conduct clinical trials for advanced malignant tumors. In April of this year, the drug had already received approval from the U.S.…
In March 2026, SYS6051, developed by CSPC Pharmaceutical Group’s Jushi Biopharmaceutical, received clinical trial approval in China for the indication of advanced solid tumors. The drug has also received clearance from the U.S. FDA to conduct clinical trials. SYS6051 is…
In March 2026, SYH2059 Inhalation Powder received a clinical trial tacit approval in China for the indication of pulmonary fibrosis. SYH2059 is a highly selective phosphodiesterase 4B (PDE4B) inhibitor developed by CSPC Pharmaceutical Group. Preclinical studies have shown that SYH2059…